2m 2m 2m 2m 2m 2m 2m
PSYENCE BIO (PBM)
NASDAQ
$3.82-$0.14 (-3.42%)
Price as of Jun 03, 2026 7:53 PM EDT- $9.5MMarket Cap
- -87.06%1-Year Change
- BiotechnologyIndustry
PSYENCE BIO (PBM)
$3.82-$0.14 (-3.42%)
Annual
Quarterly
03/31/2025 | 03/31/2024 | ||
|---|---|---|---|
Income Statement | |||
Total Operating Revenue | N/A N/A | N/A N/A | |
Cost of Revenue | N/A N/A | N/A N/A | |
Gross Profit | 0 N/A | 0 N/A | |
Sales and Marketing Expense | 483,530 +499.89% | 80,603 N/A | |
Research and Development Expense | -342,168 -64.16% | -954,593 N/A | |
Depreciation and Amortization Expense | N/A N/A | N/A N/A | |
Total Operating Expenses | 1.2M +116.86% | 557,904 N/A | |
Operating Profit | N/A N/A | N/A N/A | |
Interest Income | N/A N/A | N/A N/A | |
Interest Expense | -9,270 N/A | N/A N/A | |
Interest Income and Expense and Net | -9,270 N/A | 0 N/A | |
Total Nonoperating Income and Expense | 9,270 +101.05% | -879,344 N/A | |
Income before Taxes | 1.0M +101.98% | -51.2M N/A | |
Income Taxes | N/A N/A | N/A N/A | |
Extraordinary Items | N/A N/A | N/A N/A | |
Net Income | 1.0M +101.98% | -51.2M N/A | |
Net Income from Continuing Operations Applicable to Common | 1.0M +101.98% | -51.2M N/A | |
Basic EPS and Net Income | 5.24 +167.01% | -7.82 N/A | |
Diluted EPS and Net Income | 5.24 +167.01% | -7.82 N/A | |
Basic Weighted Average Shares | 193,043 -97.04% | 6.5M N/A | |
Diluted Weighted Average Shares | 193,043 -97.04% | 6.5M N/A | |
Balance Sheet | |||
Cash and Cash Equivalents | 6.1M +736.78% | 733,188 N/A | |
Short-Term Investments | N/A N/A | N/A N/A | |
Cash and Cash Equivalents and Short-Term Investments | 6.1M +736.78% | 733,188 N/A | |
Total Current Assets | 6.6M +482.27% | 1.1M N/A | |
Accumulated Depreciation | N/A N/A | N/A N/A | |
Property and Plant and Equipment and Net | 11,096 +102.22% | 5,487 N/A | |
Total Long-Term Assets | N/A N/A | N/A N/A | |
Total Assets | 7.3M +546.23% | 1.1M N/A | |
Income Taxes Payable | N/A N/A | N/A N/A | |
Total Short-Term Debt | N/A N/A | N/A N/A | |
Total Current Liabilities | N/A N/A | N/A N/A | |
Total Long-Term Debt | N/A N/A | N/A N/A | |
Total Long-Term Liabilities | 1.2M N/A | N/A N/A | |
Total Liabilities | 594,366 -95.09% | 12.1M N/A | |
Retained Earnings | -56.4M -1.76% | -57.5M N/A | |
Total Stockholders Equity | 6.7M +161.26% | -11.0M N/A | |
Total Shares Outstanding | 568,021 -95.76% | 13.4M N/A | |
Cash Flow | |||
Cash from Operating Activities | -3.7M +26.78% | -2.9M N/A | |
Capital Expenditures | N/A N/A | N/A N/A | |
Cash from Investing Activities | -16,230 +183.39% | -5,727 N/A | |
Dividends Paid | N/A N/A | N/A N/A | |
Cash from Financing Activities | 9.2M +289.47% | 2.4M N/A | |
Financials Ratio | |||
Gross Margin | N/A N/A | N/A N/A | |
Operating Margin | N/A N/A | N/A N/A | |
Return on Assets | 23.95% N/A | N/A N/A | |
Return on Equity | -47.61% N/A | N/A N/A | |
Revenue Growth | N/A N/A | N/A N/A | |
Current Ratio | N/A N/A | N/A N/A | |
Cash Ratio | N/A N/A | N/A N/A | |
Debt-to-Equity Ratio | N/A N/A | N/A N/A | |
Debt-to-Assets Ratio | N/A N/A | N/A N/A | |
Earnings & Revenue History
Debt-to-Assets
Cash Flow